Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Celecoxib in Preventing Breast Cancer in Premenopausal Women

Study:

Randomized Placebo-Controlled Biomarker Modulation Trial Using Celecoxib in Premenopausal Women at High Risk for Breast Cancer

Rationale:

Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be effective in preventing breast cancer.

Purpose:

This randomized phase II trial is studying how well celecoxib works in preventing breast cancer in premenopausal women who are at risk for developing the disease.

Study Status: Recruiting

Recruiting:
Clinical Trials Office - Cleveland Clinic - Wooster 800-862-7798

Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100

George T. Budd, MD 216-447-9747

Condition Intervention Phase
Breast Cancer Drug: celecoxib
Procedure: chemoprevention
Procedure: enzyme inhibitor therapy
Procedure: prostaglandin inhibition
Phase 2

Verified by Southwest Oncology Group January, 2008

Sponsored by: Southwest Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00088972

Study Type: Interventional

Study Design: Prevention, Randomized, Double-Blind, Placebo Control

Cleveland Clinic - Wooster
Wooster, Ohio 44691
United States

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States

Powel H. Brown, MD, PhD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site